Floatz logo

ANTI-PD-1/TIM-3 BISPECIFIC ANTIBODY RO7121661

Esophageal Squamous Cell Carcinoma (ESCC)

Hoffmann-La Rochemonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

65 Active assets in the Esophageal Squamous Cell Carcinoma (ESCC) cohort.

Asset / SponsorPhaseRating
Eloxatin
Taiho Oncology, Inc.
Phase 3BB
FLUOROURACILUM
AstraZeneca
Phase 3BB
Irinotecan
Taiho Oncology, Inc.
Phase 2BB
Levoleucovorin
Taiho Oncology, Inc.
Phase 3BB
Cetuximab
Hummingbird Bioscience
Phase 2B

View all 50 →

Same molecule, other indications

ANTI-PD-1/TIM-3 BISPECIFIC ANTIBODY RO7121661 is also rated in:

small cell lung carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
metastatic melanomaDormant
CC
Indicative ·
42 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →